G6PD activator AG1 manufacturers
|
| | G6PD activator AG1 Basic information |
| Product Name: | G6PD activator AG1 | | Synonyms: | G6PD activator AG1;G-6PD activator AG1,G6PD activator AG1;1H-Indole-3-ethanamine, N,N'-(dithiodi-2,1-ethanediyl)bis- (9CI);2,2'-disulfanediylbis(N-(2-(1H-indol-3-yl)ethyl)ethan-1-amine);1H-Indole-3-ethanamine, N,N′-(dithiodi-2,1-ethanediyl)bis-;2,2'-disulfanediylbis(N-(2-(1H-indol-3-yl)ethyl)ethan-1-amine) | | CAS: | 421581-52-4 | | MF: | C24H30N4S2 | | MW: | 438.65 | | EINECS: | | | Product Categories: | | | Mol File: | 421581-52-4.mol |  |
| | G6PD activator AG1 Chemical Properties |
| Boiling point | 689.8±55.0 °C(Predicted) | | density | 1.244±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C,unstable in solution, ready to use. | | solubility | DMSO: 20.83 mg/mL (47.49 mM) | | form | Oil | | pka | 16.93±0.30(Predicted) | | color | Light yellow to yellow | | InChI | InChI=1S/C24H30N4S2/c1-3-7-23-21(5-1)19(17-27-23)9-11-25-13-15-29-30-16-14-26-12-10-20-18-28-24-8-4-2-6-22(20)24/h1-8,17-18,25-28H,9-16H2 | | InChIKey | AJBHTYKMNQDUAA-UHFFFAOYSA-N | | SMILES | C(C1=CNC2=CC=CC=C21)CNCCSSCCNCCC1=CNC2=CC=CC=C12 |
| | G6PD activator AG1 Usage And Synthesis |
| Uses | G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) agonist with an EC50 of 3 μM. G6PD is an oxidoreductase that catalyzes the oxidation of glucose-6-phosphate to 6-phosphogluconolactone and the simultaneous reduction of NAD phosphate (NADP) to reduced NADP (NADPH). G6PD activator AG1 can reduce hemolysis of human erythrocytes[1][2]. | | Definition | ChEBI: N,N'-[disulfanediyldi(ethane-2,1-diyl)]bis[2-(1H-indol-3-yl)ethan-1-amine] is an organic disulfide composed of two molecules of 2-{[2-(1H-indol-3-yl)ethyl]amino}ethane-1-thiol linked together via a disulfide bond. It is a glucose-6-phosphate dehydrogenase (G6PD) activator which reduces oxidative stress in cells and zebrafish. It is an organic disulfide, a member of indoles and a secondary amino compound. | | References | [1] https://patents.google.com/patent/WO2019023264A1/enoq=WO2019023264A1
[2] Kaitlyn Ryan, et al. Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency. Pharmacol Ther. 2020 Dec 14;222:107788. DOI:10.1016/j.pharmthera.2020.107788 |
| | G6PD activator AG1 Preparation Products And Raw materials |
|